Porth Ymchwil

All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

StandardStandard

All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age. / Hughes, D.; Hughes, D.A.; All Wales Strategy Group., [No Value].
2008 gol. Unknown, 2008.

Allbwn ymchwil: Llyfr/Adroddiad › Adroddiad Comisiwn

HarvardHarvard

Hughes, D, Hughes, DA & All Wales Strategy Group., NV 2008, All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age. 2008 gol., Unknown.

APA

Hughes, D., Hughes, D. A., & All Wales Strategy Group., N. V. (2008). All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age. (2008 gol.) Unknown.

CBE

Hughes D, Hughes DA, All Wales Strategy Group. NV 2008. All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age. 2008 gol. Unknown.

MLA

Hughes, D., D.A. Hughes a [No Value] All Wales Strategy Group. All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age. 2008 udg. Unknown. 2008.

VancouverVancouver

Hughes D, Hughes DA, All Wales Strategy Group. NV. All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age. 2008 gol. Unknown, 2008.

Author

Hughes, D. ; Hughes, D.A. ; All Wales Strategy Group., [No Value]. / All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age. 2008 gol. Unknown, 2008.

RIS

TY - BOOK

T1 - All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

AU - Hughes, D.

AU - Hughes, D.A.

AU - All Wales Strategy Group., [No Value]

PY - 2008/1/1

Y1 - 2008/1/1

UR - http://www.wales.nhs.uk/sites3/Documents/371/Abacavir%20lamivudine%20(Kivexa)%20FAR%20Final%20For%20Website.pdf

M3 - Commissioned report

BT - All Wales Medicines Strategy Group Final Appraisal Report - Abacavir 600mg/lamivudine 300mg (Kivexa) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age.

PB - Unknown

ER -